Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$89.51 USD

89.51
6,484,782

+0.69 (0.78%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $89.55 +0.04 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed at $75.05 in the latest trading session, marking a -0.82% move from the prior day.

Gilead to Start Studies for an Inhaled Version of Remdesivir

by Zacks Equity Research

Gilead (GILD) announces plans to start studies for an inhaled version of the experimental candidate, remdesivir, in August.

Novartis Discontinues HCQ Study Due to Enrollment Challenges

by Zacks Equity Research

Novartis (NVS) abandons its HCQ study in COVID-19 patients due to enrollment challenges.

Regeneron Gets FDA Nod for Dupixent 300 Mg Pre-Filled Pen

by Zacks Equity Research

Regeneron (REGN) wins FDA approval for a 300-mg, single-dose, pre-filled pen for asthma drug, Dupixent.

Bet on These 5 High Earnings Yield Stocks to Book Profits

by Zacks Equity Research

Earnings yield has an edge over P/E ratio as it can be used to compare a stock with not just other stocks but also with fixed income securities.

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed the most recent trading day at $74.62, moving +0.88% from the previous trading session.

Mark Vickery headshot

Oxford Discovers COVID-19 Treatment, Plus Record Retail Sales

by Mark Vickery

Dexamethasone is a generic anti-inflammatory drug already prescribed by physicians more than a million times per year, for various conditions.

Economic Data Deluge

by Zacks Equity Research

Economic Data Deluge

Kinjel Shah headshot

FDA Ends Hydroxychloroquine's Emergency Use for Coronavirus

by Kinjel Shah

The FDA said that chloroquine and hydroxychloroquine are unlikely to prove effective in treating COVID-19 as the known benefits outweigh the risks.

Ekta Bagri headshot

3 Big Biotechs Poised for Growth Amid Coronavirus Pandemic

by Ekta Bagri

We highlight a few leading players from the biotech sector, who are likely to see a good run as the year progresses.

Lilly Begins Phase III Study on Olumiant for Coronavirus

by Zacks Equity Research

Lilly's (LLY) Olumiant is being studied for COVID-19 on the assumption that JAK1 and JAK2 inhibition may reduce cytokine storm, a complication associated with COVID-19.

Dr. Reddy's Inks Deal With Gilead Sciences for Remdesivir

by Zacks Equity Research

Dr. Reddy Laboratories (RDY) inks a deal with Gilead to register, manufacture and sell the latter's Remdesivir ??? a potential treatment for COVID-19 ??? in 127 countries including India.

Roche (RHHBY) Presents Positive Data on Venclexta at EHA 2020

by Zacks Equity Research

Roche (RHHBY) provides pipeline updates at the EHA Virtual Congress Press Briefing.

GILD vs. ILMN: Which Stock Is the Better Value Option?

by Zacks Equity Research

GILD vs. ILMN: Which Stock Is the Better Value Option?

Regeneron Initiates Study on Antibody Cocktail for Coronavirus

by Zacks Equity Research

Regeneron (REGN) initiates study on its antibody cocktail, REGN-COV2, for the prevention and treatment of COVID-19.

Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed at $77.07 in the latest trading session, marking a -0.67% move from the prior day.

Gilead Up on Report of AstraZeneca's Interest in Merger

by Zacks Equity Research

Gilead (GILD) gains after report surfaces that AstraZeneca has shown interest in the former last month.

Company News for Jun 9, 2020

by Zacks Equity Research

Companies In The News Are: THO, ROKU, GILD, AZN, TSLA.

Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (GILD) Outperforming Other Medical Stocks This Year?

AbbVie (ABBV) Joins Race for Developing Coronavirus Treatment

by Zacks Equity Research

AbbVie (ABBV) collaborates with three parties for developing an antibody-based treatment for COVID-19.

Ritujay Ghosh headshot

Drugmakers Target Coronavirus Vaccine in 2020: 4 Stocks in Focus

by Ritujay Ghosh

Several drugmakers have started ramping up production, anticipating huge demand if the candidates prove successful.

AstraZeneca Reportedly Approaches Gilead for Potential Merger

by Zacks Equity Research

If AstraZeneca (AZN) and Gilead (GILD) were to combine into one, it would be the biggest health-care deal ever.

Gilead's Rating Upgraded on Potential Coronavirus Drug Sales

by Zacks Equity Research

Gilead (GILD) rides high on potential sales from its experimental coronavirus treatment, remdesivir, and collaboration with Arcus.

Roche's COVID-19 Test Gets FDA's Emergency Use Authorization

by Zacks Equity Research

Roche's (RHHBY) Elecsys IL-6 test gets FDA's EUA for identifying patients at high risk of severe inflammatory response.

Sweta Jaiswal, FRM headshot

How Are Biotech ETFs Reacting to Coronavirus Treatment News?

by Sweta Jaiswal, FRM

Here we take a look at how the latest updates on drugs, antibody therapies and vaccines targeted at winning the coronavirus battle can affect biotech ETFs.